

Supplemental Table S2. Weight Change, Food Intake, and Serum Glucose and Lipid Profiles

Variable	<i>ApoE</i> ^{-/-}		<i>ApoE</i> ^{-/-} <i>FXR</i> ^{-/-}		P value ^a	P value ^b
	WD (n=7)	WD (n=9)	WD+pioglitazone (n=8)	WD+fenofibrate (n=9)		
Initial body weight, g	27.8±0.9	23.7±2.0	21.1±2.6	20.9±2.1	<0.001	0.038
Final body weight, g	34.7±4.4	32.9±5.1	31.1±5.4	27.2±2.2	0.541	0.031
Weight change, g	7.0±4.0	9.2±4.7	9.9±0.2	6.2±1.6	0.481	0.620
Food intake, g/day	2.90±0.93	2.87±0.23	3.17±0.01	3.09±0.30	0.774	0.001
Survival, %	100	100	100	100		
Fasting glucose, mg/dL	134±32	128±20	133±14	130±14	0.606	0.884
Lipid profile						
Total cholesterol, mg/dL	691±152	1,091±176	786±117	993±219	0.017	0.119
Triglycerides, mg/dL	179±49	289±52	310±35	190±73	0.016	0.028 ^c
HDL-C, mg/dL	47±27	54±22	57±16	48±16	0.683	0.781
LDL-C, mg/dL	574±79	798±135	633±59	721±152	0.008	0.136

Values are expressed as mean ± standard deviation.

ApoE, apolipoprotein E; *FXR*, farnesoid X receptor; WD, Western diet; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

^aComparison between *ApoE*^{-/-} vs *ApoE*^{-/-}*FXR*^{-/-} on Western diet only by Kruskal-Wallis test; ^bComparison among *ApoE*^{-/-}*FXR*^{-/-} on Western diet with or without pioglitazone/fenofibrate; ^c*P*<0.05 between *ApoE*^{-/-}*FXR*^{-/-} subjects treated with pioglitazone and subjects treated with fenofibrate only, on *post hoc* analysis.